KSL Diagnostics offers integrated clinical services focused on providing diagnostic, prognostic, therapeutic and disease-monitoring information. Our flexible and collaborative approach enables personalized medicine by making advanced clinical disease management tools available to oncologists, pathologists and cytogenetic groups. We provide information to help you make critical healthcare decisions and improve patient outcomes.
Our clinical services are driven by our expertise in molecular biology, cytogenetics, and the development of custom assays. We provide comprehensive support services throughout all stages of your project, from development and implementation, to reporting and follow up.
KSL Diagnostics maintains a high standard of quality through our CAP and CLIA certified facility, holding licenses from the states of New York, Pennsylvania, California and Maryland. Our FDA-registered lab holds a certificate of accreditation from the Centers for Medicare and Medicaid Services under CLIA (CLIA: 33D2043745), and is accredited by the College of American Pathologists. Our NPI is 1265853519.
Integrated Disease Management
KSL Diagnostics works together with oncologists and pathologists to provide an integrated continuum of care. By combining information from complementary tests with an individual’s medical history, healthcare providers can develop targeted treatment and prevention plans that are centered around the patient. We engage in real time discussions of cases, ensuring appropriate actions are taken in a timely manner, ultimately resulting in the best concerted patient care.
Our expertise and focus on providing solutions, rather than offering technologies, is what sets us apart from other companies offering molecular and cytogenetic testing. We provide insight on the strengths and weaknesses of a given technology and work with you to select the best fit for your clinical needs.
While our approach is tailored to each practice's needs, every client can expect the following support:
Clear informative results
Test utilization management
Transparency on turnaround time (TAT)
Integration with specialty practices
Consultations on testing results and implications